PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer

RecruitingOBSERVATIONAL
Enrollment

150

Participants

Timeline

Start Date

October 15, 2022

Primary Completion Date

October 15, 2026

Study Completion Date

September 1, 2027

Conditions
Endometrial Cancer Stage IIIEndometrial Cancer Stage IVEndometrial Cancer Recurrent
Interventions
DRUG

Hormonal Antineoplastics

Hormonal therapy used for treatment in endometrial cancer patients

Trial Locations (1)

6525GA

RECRUITING

Radboudumc, Nijmegen

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Haukeland University Hospital

OTHER

collaborator

Maastricht University Medical Center

OTHER

collaborator

Brno University Hospital

OTHER

collaborator

Holycross Cancer Center Kielce

UNKNOWN

collaborator

Medical University of Lublin

OTHER

collaborator

Hospital del Mar

OTHER

collaborator

Hospital Vall d'Hebron

OTHER

collaborator

Royal Cornwall Hospitals Trust

OTHER

collaborator

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

collaborator

The Netherlands Cancer Institute

OTHER

collaborator

Canisius-Wilhelmina Hospital

OTHER

collaborator

Catharina Ziekenhuis Eindhoven

OTHER

collaborator

Erasmus Medical Center

OTHER

collaborator

Leiden University Medical Center

OTHER

lead

Radboud University Medical Center

OTHER